Evaluating the clinical effectiveness and safety of insulin glargine 300 U/ mL in individuals with type 2 diabetes uncontrolled on basal insulin: A real‐world evidence study from Saudi Arabia ( EVOLUTION )
Main finding · Change in mean HbA1cResult — go to the resultMean reduction 0.7 % 95% CI 0.6%–0.9%Authors' conclusion
Real-world evidence supports the effectiveness of switching to Gla-U300 from first-generation basal insulin in T2D in Saudi Arabia.
Study context
- Population
- Adults with T2D uncontrolled on basal insulin, switched to insulin glargine 300 U/mL (Gla-U300) for poor glycaemic control, Saudi Arabiaanalysed
- Participants
- 718 adults
- Exposure
- After vs before switching to Gla-U300
- Outcome
- Change in mean HbA1c
- Follow-up
- 6 months after switch
Methodological detailsmulticentre, real-world, before-after switch comparison
- Multicentre
- Real-world
- Before-after switch comparison
Main finding
As reported in the abstract
Mean reduction
0.7 %
95% CI 0.6%–0.9%
P < 0.001
Observational data: associations, not effects.
Further findings
HbA1c <7%
Individualized HbA1c goal achieved
Daily insulin dose · spread printed as ±
P = 0.09
Initial dose adjustment required
- Patients requiring adjustment to initial dose
- About 36.1
Safety
Overall confirmed or symptomatic hypoglycaemia
Severe hypoglycaemia
Overall confirmed or symptomatic hypoglycaemia
- Gla-U300 was well tolerated
Original publication
Evaluating the clinical effectiveness and safety of insulin glargine 300 U/ mL in individuals with type 2 diabetes uncontrolled on basal insulin: A real‐world evidence study from Saudi Arabia ( EVOLUTION ). Diabetes Obes Metab. Published 24 July 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →